135 related articles for article (PubMed ID: 33345726)
21. Interaction and inhibition of dengue envelope glycoprotein with mammalian receptor DC-sign, an in-silico approach.
Shah M; Wadood A; Rahman Z; Husnain T
PLoS One; 2013; 8(3):e59211. PubMed ID: 23527139
[TBL] [Abstract][Full Text] [Related]
22. A Benzene-Mapping Approach for Uncovering Cryptic Pockets in Membrane-Bound Proteins.
Zuzic L; Marzinek JK; Warwicker J; Bond PJ
J Chem Theory Comput; 2020 Sep; 16(9):5948-5959. PubMed ID: 32786908
[TBL] [Abstract][Full Text] [Related]
23. Small-molecule inhibitors of dengue-virus entry.
Schmidt AG; Lee K; Yang PL; Harrison SC
PLoS Pathog; 2012; 8(4):e1002627. PubMed ID: 22496653
[TBL] [Abstract][Full Text] [Related]
24. Anti-dengue infectivity evaluation of bioflavonoid from
Dwivedi VD; Bharadwaj S; Afroz S; Khan N; Ansari MA; Yadava U; Tripathi RC; Tripathi IP; Mishra SK; Kang SG
J Biomol Struct Dyn; 2021 Mar; 39(4):1417-1430. PubMed ID: 32107969
[TBL] [Abstract][Full Text] [Related]
25. Acidic pH-Induced Conformational Changes in Chikungunya Virus Fusion Protein E1: a Spring-Twisted Region in the Domain I-III Linker Acts as a Hinge Point for Swiveling Motion of Domains.
Sahoo B; Gudigamolla NK; Chowdary TK
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938768
[TBL] [Abstract][Full Text] [Related]
26. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.
Mirza SB; Salmas RE; Fatmi MQ; Durdagi S
J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972
[TBL] [Abstract][Full Text] [Related]
27. Extensive structural change of the envelope protein of dengue virus induced by a tuned ionic strength: conformational and energetic analyses.
Degrève L; Fuzo CA; Caliri A
J Comput Aided Mol Des; 2012 Dec; 26(12):1311-25. PubMed ID: 23160852
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors.
Jadav SS; Kaptein S; Timiri A; De Burghgraeve T; Badavath VN; Ganesan R; Sinha BN; Neyts J; Leyssen P; Jayaprakash V
Bioorg Med Chem Lett; 2015 Apr; 25(8):1747-1752. PubMed ID: 25791449
[TBL] [Abstract][Full Text] [Related]
29. Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus.
Anasir MI; Ramanathan B; Poh CL
Viruses; 2020 Mar; 12(4):. PubMed ID: 32225021
[TBL] [Abstract][Full Text] [Related]
30. Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal.
Viswanathan U; Tomlinson SM; Fonner JM; Mock SA; Watowich SJ
J Chem Inf Model; 2014 Oct; 54(10):2816-25. PubMed ID: 25263519
[TBL] [Abstract][Full Text] [Related]
31. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection.
Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143
[TBL] [Abstract][Full Text] [Related]
32. Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies.
Qaddir I; Rasool N; Hussain W; Mahmood S
J Vector Borne Dis; 2017; 54(3):255-262. PubMed ID: 29097641
[TBL] [Abstract][Full Text] [Related]
33. Looking for inhibitors of the dengue virus NS5 RNA-dependent RNA-polymerase using a molecular docking approach.
Galiano V; Garcia-Valtanen P; Micol V; Encinar JA
Drug Des Devel Ther; 2016; 10():3163-3181. PubMed ID: 27784988
[TBL] [Abstract][Full Text] [Related]
34. Scaffold identification and drug repurposing for finding potential Dengue envelope inhibitors through ligand-based pharmacophore model.
Priya S; Alli VJ; Jadav SS
J Biomol Struct Dyn; 2023; 41(21):11916-11929. PubMed ID: 36709443
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel target sites and an inhibitor of the dengue virus E protein.
Yennamalli R; Subbarao N; Kampmann T; McGeary RP; Young PR; Kobe B
J Comput Aided Mol Des; 2009 Jun; 23(6):333-41. PubMed ID: 19241120
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein.
Lian W; Jang J; Potisopon S; Li PC; Rahmeh A; Wang J; Kwiatkowski NP; Gray NS; Yang PL
ACS Infect Dis; 2018 Sep; 4(9):1395-1406. PubMed ID: 30027735
[TBL] [Abstract][Full Text] [Related]
37. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
[TBL] [Abstract][Full Text] [Related]
38. Computational-aided design: minimal peptide sequence to block dengue virus transmission into cells.
Arumugam AC; Agharbaoui FE; Khazali AS; Yusof R; Abd Rahman N; Ahmad Fuaad AAH
J Biomol Struct Dyn; 2022 Jul; 40(11):5026-5035. PubMed ID: 33382015
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the suitability of RNA intervention mechanism exerted by some flavonoid molecules against dengue virus MTase RNA capping site: a molecular docking, molecular dynamics simulation, and binding free energy study.
Manjula S; Kumaradhas P
J Biomol Struct Dyn; 2020 Aug; 38(12):3533-3543. PubMed ID: 31514688
[TBL] [Abstract][Full Text] [Related]
40. Antiviral phytochemicals as potent inhibitors against NS3 protease of dengue virus.
Rahman MM; Biswas S; Islam KJ; Paul AS; Mahato SK; Ali MA; Halim MA
Comput Biol Med; 2021 Jul; 134():104492. PubMed ID: 34022487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
